The present study aimed to ascertain the efficacy of an MLE containing the pseudoceramide PC-9S as well as the SPHK1 activator DefensamideTM on AD, extending its scope to patients with AD aged ≥ 2 years, encompassing pediatric patients and beyond. Here, SPHK1 is linked to Alzheimer disease.